Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.

Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.

Vertex Pharmaceuticals is focused on discovering, developing and producing innovative medicines so people with serious diseases can lead better lives.

Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.

At Vertex, we believe "impossible" is just a starting point. We’re not limited by what we’ve done before. We’re leveraging our robust toolkit of technologies and expertise to tackle other serious diseases like cystic fibrosis, sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes and more.

The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.

Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.

Dec 20, 2024 · BOSTON --(BUSINESS WIRE)--Jan. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people living with serious diseases, with a focus on specialty markets.

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis